/
IOVA
$6.52-$0.22 (-3.26%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.1B
453M shares
52-week range
$1.76 – $6.92
92% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-14.47
Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
www.iovance.com- Employees
- 975
- IPO / List date
- May 26, 2010
- HQ
- SAN CARLOS, CA
Held by traders on TradeandTell
No one on the platform currently holds IOVA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 651,000 | $1.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IOVA yet.
